Table 3.
Respiratory Tract and CNS Infection Assays
Organism | Specimen/sample type | Platform/assay (FDA no.) | Method | Target | Sensitivity (%)⁎ | Specificity (%)⁎ |
---|---|---|---|---|---|---|
Respiratory virus panel: influenza A/H1 and A/H3; influenza B; adenovirus; RSV; metapneumovirus (hMPV); parainfluenza (hPIV) 1, 2, and 3; and rhinovirus | Nasopharyngeal swab | xTAG Respiratory Viral Panel (K063765)† | RT-PCR, allele-specific primer extension, tag sorting | Matrix gene of influenza A, Hemagglutinin gene of influenza A/H1 and A/H3 | Influenza A, 96.4 | Influenza A, 95.9 |
Influenza B, adenovirus, RSV A/B metapneumovirus | Influenza A/H1, 100 | Influenza A/H1, 100 | ||||
Parainfluenza 1, 2, and 3; and rhinovirus | Influenza A/H3, 91.7 | Influenza A/H3, 98.7 | ||||
Influenza B, 91.5 | Influenza B, 96.7 | |||||
RSV A, 100 | RSV A, 98.4 | |||||
RSV B, 100 | RSV B, 97.4 | |||||
Adenovirus, 78.3 | Adenovirus, 100 | |||||
hMPV, 96 | hMPV, 98.8 | |||||
hPIV 1, 100 | hPIV 1, 99.8 | |||||
hPIV 2, 100 | hPIV 2, 99.8 | |||||
hPIV 3, 84.2 | hPIV 3, 99.6 | |||||
Rhinovirus, 100 | Rhinovirus, 91.3 | |||||
Respiratory virus panel: influenza A and B and RSV | Nasopharyngeal swab, cultured clinical specimens | Verigene Respiratory Virus Nucleic Acid Test (K083088)‡ and Verigene Respiratory Virus Nucleic Acid Test on the Verigene SP system (K092566)‡ | Multiplex RT-PCR multiplex gold nanoparticle hybridization technology Verigene System‡ | Influenza A matrix gene | Influenza A, 99.2 | Influenza A, 90.1 |
Influenza B NS and matrix genes | Influenza B, 96.8 | Influenza B, 98.5 | ||||
L and F genes of RSV | RSV, 89.8 | RSV, 91.5 | ||||
Nasopharyngeal swab | ProFlu+ (K073029, K081030, K092500)§ and SmartCycler¶ | Multiplex real-time RT-PCR TaqMan chemistry | Influenza A matrix gene | Influenza A, 100 | Influenza A, 92.6 | |
Influenza B non-structural NS1 and NS2 genes | Influenza B, 97.8 | Influenza B, 98.6 | ||||
RSV polymerase gene | RSV, 89.5 | RSV, 94.9 | ||||
Respiratory virus panel: influenza A and B and RSV | Nasopharyngeal swab | Simplexa Flu A/B and RSV (K102170)∥; MagNA Pure LC Instrument and the MagNA Pure Total Nucleic Acid Isolation Kit⁎⁎ or a Qiagen QIAamp Viral RNA Mini Kit†† and 3M Integrated Cycler‡‡ | Real-time RT-PCR | Target RNA of highly conserved region of matrix protein genes of influenza A and B and RSV | Influenza A, 100 | Influenza A, 99.3 |
Influenza B, 100 | Influenza B, 99.8 | |||||
RSV, 98 | RSV, 96.9 | |||||
Respiratory virus: influenza A/H1N1-2009 | Nasopharyngeal swabs, nasal swabs, NPAs | Simplexa Influenza A H1N1 (2009) (K100148)∥; MagNA Pure LC Instrument and the MagNA Pure Total Nucleic Acid Isolation Kit⁎⁎ or a Qiagen QIAamp Viral RNA Mini Kit†† and 3M Integrated Cycler‡‡ | Real-time PCR | Influenza A matrix gene and unique region in Hemagglutinin gene of 2009 H1N1 influenza virus | % positive agreement for swabs, 100; NPA, 100 | % negative agreement for swabs, 92.5; NPA, 96.1 |
Respiratory virus: influenza A/H1N1-2009 | Nasopharyngeal swabs and nasal swabs | CDC Human Influenza Virus Real-Time RT-PCR Detection and Characterization Panel (K101564)§§ and Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument¶¶ | Real-time PCR | Influenza A matrix gene and Nucleoprotein gene specific for 2009 H1N1 and Hemagglutinin gene specific for 2009 H1N1 | 96 | 96 |
Respiratory virus panel: seasonal influenza A/H1, A/H3, and A/H1N1-2009 | Nasopharyngeal swab | ProFAST+ (K101855)§ and SmartCycler¶ | Real-time RT-PCR | Target RNA of conserved region of Hemagglutinin gene | % positive agreement for A/H1, 100; A/H3, 100; A/H1N1-2009, 95.4 | % negative agreement for A/H1, 99.0; A/H3, 99.0; A/H1N1-2009, 100 |
Respiratory virus: influenza A/H5 (Asian lineage) | Nasopharyngeal and throat swabs | JBAIDS Influenza A subtype A/H5 (Asian lineage) (K100287) ∥∥ and JBAIDS Instrument | Real-time RT-PCR | Two target RNA sequences 5′ and 3′ of the Hemagglutinin precursor cleavage site within the conserved regions of the Hemagglutinin gene of influenza A/H5 (Asian lineage) virus | 96.9–100 | 95.3–97.1 |
Respiratory virus: hPIV | Nasopharyngeal swab | ProParaFlu+ (K091053)§ and SmartCycler¶ | Multiplex real-time RT-PCR TaqMan chemistry | Conserved regions of Hemagglutinin-Neuraminidase gene of hPIV 1, 2, and 3 | hPIV-1, 88.9 | hPIV-1, 99.9 |
hPIV-2, 96.3 | hPIV-2, 99.8 | |||||
hPIV-3, 97.3 | hPIV-3, 99.2 | |||||
Respiratory virus: hMPV | Nasopharyngeal swab | Pro hMPV+ (K082688)§ and SmartCycler¶ | Real-time RT-PCR TaqMan chemistry | hMPV: Nucleocapsid gene | % positive agreement, 94.1 | % negative agreement, 99.3 |
Respiratory virus: adenovirus | Nasopharyngeal swab | ProAdeno+ (K102952)§ and SmartCycler¶ | Multiplex real-time PCR TaqMan chemistry | Adenovirus serotypes 1–51, Hexon gene | 97.5 | 95.6 |
Enterovirus | CSF | Xpert EV (K061062) and GeneXpert System¶ | Real-time PCR | Consensus region of enterovirus, 5′ UTR between nucleotides 452 and 596 | 96.3–100 | 97.0–97.2 |
CSF | NucliSENS EasyQ Enterovirus (K063261)⁎⁎⁎ and NucliSENS EasyQ System | NASBA | Enterovirus RNA | 70.9–100 | 99.3–100 | |
MTB | Sputum and bronchial specimens | AMPLIFIED MTD (Mycobacterium Tuberculosis Direct) Test (P940034/S008)††† | Transcription- mediated amplification, hybridization protection assay | Mycobacterial 16S rRNA | 96.9 | 100 |
hMPV, human metapneumovirus; hPIV, human parainfluenza virus; NASBA, nucleic acid sequence-based amplification; NPA, nasopharyngeal aspirate.
Sensitivity, specificity, and percentage positive or negative agreement with culture data are sourced from FDA submission material or product inserts.
Obtained from Luminex Corporation, Austin, TX.
Obtained from Nanosphere, Inc., Northbrook, IL.
Obtained from Gen-Probe Prodesse, Inc., Waukesha, WI.
Obtained from Cepheid, Sunnyvale, CA.
Obtained from Focus Diagnostics, Inc., Cypress, CA.
Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
Obtained from Qiagen, Gaithersburg, MD.
3M, St Paul, MN.
Obtained from the CDC, Atlanta, GA.
Obtained from Life Technologies Inc., Carlsbad, CA.
Obtained from bioMérieux Inc., Durham, NC.
Obtained from Gen-Probe, Inc., San Diego, CA.
Obtained from the Department of Defense.